TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
|Articles|January 1, 2000
The American Journal of Managed Care
- January 2000
- Volume 6
- Issue 1
Parkinson's Disease: Focus on Management Alternatives
Advertisement
Articles in this issue
almost 27 years ago
The Impact of Health Insurance Market Reforms on Market Competitionalmost 27 years ago
Acne Vulgaris: Pathogenesis and Therapeutic Approachalmost 27 years ago
The Future of Health Status Assessmentalmost 27 years ago
Regulating the Pharmaceutical Industry: Who Really Benefits?almost 27 years ago
Can Peer-Comparison Feedback Improve Patient Functional Status?almost 27 years ago
Preventive Service Use and Medicaid Managed Care in New York CityAdvertisement
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5